Advancing AAV Purification: New Approaches to Improve Performance and Reduce Cost
Webinar
AAV-based gene therapies hold transformative potential, but high manufacturing costs remain a critical barrier to patient access. Purification is one of the biggest cost drivers, and improving it is key to making these therapies affordable at market scale.
In this webinar, our experts will discuss current challenges in AAV purification and explore emerging approaches designed to improve efficiency, consistency, and cost-effectiveness. The session will highlight the evaluation of a reusable purification solution for AAV9, one of the most widely used AAV serotypes, and discuss key considerations for implementing next-generation purification strategies in gene therapy workflows.
In this webinar, you will learn:
- How Nanofitin® affinity ligand technology enhances AAV9 capture chromatography
- How high binding capacities at low flow rates improve overall performance
- How process modeling supports scale-up, incorporates resin reuse, and ultimately reduces manufacturing costs
Speakers
Peter Menstell
Merck
Senior Scientist
Peter Menstell is a Senior Scientist at Merck with a focus on bioprocess development. He brings more than 10 years of experience in affinity and ion-exchange chromatography media development. Previously, he focused on high-throughput screening of chromatography resin prototypes using automated liquid handling. He now serves as the technical project lead for a Nanofitin® affinity ligand-based chromatography resin, driving innovative purification solutions for recombinant proteins and other modalities in the viral and gene therapy market.
Dr. Carl Christel
Revvity
Sr. BD Manager, CGT - Europe - Revvity
Dr. Christel has spent more than a decade building, selling, and communicating viral vector services on a global scale. Now focused on the European cell and gene therapy market, he bridges the gap between CGT developers and Revvity's broad portfolio of cutting-edge solutions. He connects the right tools to the right teams, while fostering collaboration between developers inside and outside of Revvity. His passion lies in contributing to the development of life-changing gene therapies — helping them reach the world.
Pharma and biopharma manufacturing
- Gene therapy manufacturing
Duration:1h
Language:English
Session 1:Thu, August 20, 2026 3:00 PM CEST